Enhancement of intestinal absorption of 2-methyl cytidine prodrugs

Drug Delivery

Volumn 17, Issue 4, 2010, Pages 214-222

  Cianetti, Simona ^a   Cooper, Vincent Brett ^b   Attenni, Barbara ^a   Pucci, Vincenzo ^a,b   Fiore, Fabrizio ^a   Giuliano, Claudio ^a   Laufer, Ralph ^a   Gardelli, Cristina ^a   Monteagudo, Edith ^a   Narjes, Frank ^a   Pearce, Gareth Edward ^b   Rowley, Michael ^a  

^a IRBM   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Absorption promoters; Hepatitis C; Liver; Nucleosides; Triphosphate

Indexed keywords

ALPHA TOCOPHEROL; CYTIDINE DERIVATIVE; MACROGOL 10000; OCTANOIC ACID; PHOSPHORAMIDIC ACID DERIVATIVE; R 7128; SUCCINIC ACID; VALOPICITABINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG DIFFUSION; DRUG DOSAGE FORM; DRUG PENETRATION; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CACO-2 CELLS; CYTIDINE; DRUG SYNERGISM; HUMANS; INTESTINAL ABSORPTION; MALE; MICE; MICE, KNOCKOUT; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77951471519     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717541003667814     Document Type: Article

References (33)

1. Aungst, B.J. (2000). Intestinal permeation enhancers. J Pharm Sci. 89:429-442
2. Cano-Cebrian, M.J., Zornoza, T., Granero, L., Polache, A. (2005). Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv. 2:9-22.
3. Carroll, S., Bailey, C., Bosserman, M., Burlein, C., Simcoe, A., Fay, J., Ludmerer, S., Graham, D., LaFemina, R., Flores, O., Hazuda, D., Altamura, S., Migliaccio, G., Tomei, L., De Francesco, R., Summa, V., Olsen, D. (2004). Susceptibility of different genotypes of hepatitis C virus to inhibition by nucleoside and nonnucleoside inhibitors. Antiviral Res. 62:A83.
4. Carroll, S., Koeplinger, K., Vavrek, M., Handt, L., MacCoss, M., Hecker, S., Olsen, D. (2009). Administration of a HepDirectTM prodrug of 2′-C-methylcytidine to hepatitis C virus infected chimpanzees. Oral presentation at the twenty-second international conference on antiviral research. Miami Beach Resort & Spa, Miami, Florida, US - May the 3rd - May the 7th, 2009 (http:// isar.phrm.cf.ac.uk/node/58
5. Constantinides, P.P., Han, J., Davis, S.S. (2006). Advances in the use of tocols as drug delivery vehicles. Pharm Res. 23:243-255
6. Constantinides, P.P., Wasan, K.M. (2007). Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (Pgp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci. 96:235-248
7. Cornaire, G., Woodley, J., Hermann, P., Cloarec, A., Arellano, C., Houin, G. (2004). Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm. 278:119-131
8. Davies, B., Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res. 7:1093-1096
9. De Francesco, F., Carfi, A. (2007). Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev. 59:1242-1262
10. De Francesco, R., Migliaccio, G. (2005). Challenges and successes in developing new therapies for hepatitis C. Nature Insight Rev. 436:953-960
11. Dintman, J.M., Silverman, J.A. (1999). Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 16:1550-1556
12. Donghi, M., Attenni, B., Gardelli, C., Di Marco, A., Fiore, F., Giuliano, C., Laufer, R., Leone, J.F., Pucci, V., Rowley, M., Narjes, F. (2009). Synthesis and evaluation of novel phosphoramidate prodrugs of 20-methyl cytidine as inhibitors of hepatitis c virus NS5B polymerase. Bioorg Med Chem Lett. 19: 1392-1395
13. Friche, E., Jensen, P.B., Sehested, M., Demant, E.J., Nissen, N.N. (1990). The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun. 2:297-303. (Pubitemid 20380453)
14. Gane, E.J., Rodriguez-Torres, M., Nelson, D.R. (2008). Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. 59 th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco. 31 October-4 November. Abstract LB10. Available online at: http:// www.natap.org/2008/AASLD/AASLD-20.htm, accessed 23 October 2009.
15. Gonzalez-Mariscal, L., Betanzos, A., Avila-Flores, A. (2000). MAGUK proteins: structure and role in the tight junction. Cell Dev Biol. 11:315-324
16. Imai, T., Sakai, M., Ohtake, H., Azuma, H., Otagiri, M. (1999). In vitro and in vivo evaluation of the enhancing activity of glycyrrhizin on the intestinal absorption of drugs. Pharm Res.16:80-86
17. Leeson, P.D., Davis, A.M. (2004). Time-related differences in the physical property profiles of oral drugs. J Med Chem. 47:6338-6348
18. Lennernas, H., Gjellan, K., Hallgren, R., Graffner, C. (2002). The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. J Pharm Pharmacol. 54:499-508.
19. Lindmark, T., Soderholm, J.D., Olaison, G., Alvan, G., Ocklind, G., Artursson, P. (1997). Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm Res. 14:930-935
20. Loe, D.W., Sharom, F.J. (1993). Interaction of multidrug-resistant Chinese hamster ovary cells with amphiphiles. Br J Cancer. 68:342-351
21. Ludmerer, S.W., Graham, D.J., Boots, E., Murray, E.M., Simcoe, A., Markel, E.J., Grobler, J.A., Flores, O.A., Olsen, D.B., Hazuda, D.J., LaFemina, R.L. (2005). Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother. 49:2059-2069
22. Majumdar, S., Mitra, A.K. (2006). Chemical modification and formulation approaches to elevated drug transport across cell membranes. Exp Opin Drug Deliv. 3:511-527
23. Matter, K., Balda, M.S. (2003). Holey barrier: claudins and the regulation of brain endothelial permeability. J Cell Biol. 161:459-460
24. Miyoshia, J., Takai, Y. (2005). Molecular perspective on tightjunction assembly and epithelial polarity. Adv Drug Deliv Rev. 57:815-855
25. Motlekar, N.A., Srivenugopal, K.S., Watchel, M.S., Youan, B.C. (2005). Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J Drug Target. 13:573-583
26. Otto, M.J., Robson, R., Rodriguez, C.A., Beard, A., Symonds, W.T., Hill, G., Berrey, M.M. (2007). Pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside polymerase inhibitor for HCV following single, ascending oral doses in healthy volunteers. 14th International Symposium on Hepatitis C Virus and Related Viruses Glasgow, Scotland, P-268. Available online at: http://www.pharmasset.com/pipeline/R7128-publications.asp, accessed 23 October 2009.
27. Pucci, V., Giuliano, C., Zhang, R., Koeplinger, K.A., Leone, J.F., Monteagudo, E., Bonelli, F. (2009). HILIC LC-MS for the determination of 2′-C-methyl-cytidine-triphosphate in rat liver. J Sep Sci. 32:1275-1283
28. Rama-Prasad, Y.V., Puthli, S.P., Sudarat, E., Makoto, I., Yukako, Y., Nobuhito, S., Kanjii, T. (2003). Enhanced intestinal anbsorption of vancomycin with Labrasol and D-α-tocopheryl PEG 1000 succinate in rats. Int J Pharm. 250:181-190
29. Raoof, A.A., Ramtoola, Z., McKenna, B., Yu, R.Z., Hardee, G., Geary, R.S. (2002). Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci. 17:131-138
30. Regev, R., Assaraf, Y.G., Eytan, G.D. (1999). Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem. 259:18-24.
31. Sakaeda, T., Okamura, N., Nagata, S., Yagami, T., Horinouchi, M., Okumura, K., Yamashita, F., Hashida, M. (2001). Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. Biol Pharm Bull. 24:935-940
32. Sakai, M., Imai, T., Ohtake, H., Azuma, H., Otagiri, M. (1997). Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy. J Pharm Sci. 86:779-785
33. Sakai, M., Imai, T., Ohtake, H., Otagiri, M. (1998). Cytotoxicity of absorption enhancers in Caco-2 cell monolayers. J Pharm Pharmacol. 50:1101-1108